Clearmind Medicine's CMND-100 Meets Primary Endpoint

Clearmind Medicine Inc. announced that its CMND-100 drug candidate has successfully met the primary endpoint in an FDA-approved Phase I/IIa clinical trial. The trial specifically targeted patients with alcohol use disorder, indicating a significant step forward for the company's therapeutic development. This positive result suggests CMND-100 may offer a viable new treatment option for individuals struggling with alcohol dependence, potentially leading to future regulatory approvals.